ECSP20042640A - Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer - Google Patents
Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimerInfo
- Publication number
- ECSP20042640A ECSP20042640A ECSENADI202042640A ECDI202042640A ECSP20042640A EC SP20042640 A ECSP20042640 A EC SP20042640A EC SENADI202042640 A ECSENADI202042640 A EC SENADI202042640A EC DI202042640 A ECDI202042640 A EC DI202042640A EC SP20042640 A ECSP20042640 A EC SP20042640A
- Authority
- EC
- Ecuador
- Prior art keywords
- alzheimer
- disease
- prevention
- treatment
- tetrahidro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Testing Relating To Insulation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos novedosos que pueden emplearse en el tratamiento, alivio o prevención de un grupo de trastornos y anomalías asociados con los agregados de proteínas Tau (unidad asociada a tubulina) que incluyen, entre otros, los ovillos neurofibrilares (NFT), tal como la enfermedad de Alzheimer (AD).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18150422 | 2018-01-05 | ||
EP18175852 | 2018-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP20042640A true ECSP20042640A (es) | 2020-09-30 |
Family
ID=65010781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202042640A ECSP20042640A (es) | 2018-01-05 | 2020-07-22 | Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP3735411A1 (es) |
JP (2) | JP7225251B2 (es) |
KR (1) | KR102477105B1 (es) |
CN (1) | CN111757882B (es) |
AU (2) | AU2019205087B2 (es) |
BR (1) | BR112020012833A2 (es) |
CA (1) | CA3086759A1 (es) |
CL (1) | CL2020001796A1 (es) |
CO (1) | CO2020008287A2 (es) |
CR (1) | CR20200326A (es) |
EC (1) | ECSP20042640A (es) |
IL (1) | IL275781B2 (es) |
JO (1) | JOP20200167A1 (es) |
MA (1) | MA51520A (es) |
MX (1) | MX2020007031A (es) |
NZ (1) | NZ765495A (es) |
PE (1) | PE20211090A1 (es) |
PH (1) | PH12020500573A1 (es) |
SG (1) | SG11202005607WA (es) |
WO (1) | WO2019134978A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3941477A1 (en) * | 2019-03-01 | 2022-01-26 | AC Immune SA | Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates |
CN110845457B (zh) * | 2019-10-22 | 2022-06-10 | 中国药科大学 | 松萝酸衍生物及其制法和在阿尔茨海默病药物中的应用 |
CN116059192A (zh) * | 2019-11-13 | 2023-05-05 | 润佳(苏州)医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
JP2023517749A (ja) | 2020-03-19 | 2023-04-26 | エーシー イミューン エス.エー. | タウオパチーの投薬治療 |
US20240002375A1 (en) * | 2020-07-02 | 2024-01-04 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the tre |
KR102231446B1 (ko) * | 2021-01-21 | 2021-03-24 | (주) 와이디생명과학 | 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물 |
WO2023025109A1 (zh) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
WO2023133217A1 (en) * | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
KR20240045898A (ko) * | 2022-09-30 | 2024-04-08 | 김상재 | 4r 타우병증의 치료 또는 예방용 펩티드 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1585520A1 (en) | 2002-12-24 | 2005-10-19 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
AR049300A1 (es) * | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
US20090023756A1 (en) * | 2006-02-23 | 2009-01-22 | Pfizer Inc | Substituted quinazolines as pde10 inhibitors |
DK2247592T3 (da) * | 2008-02-25 | 2011-09-26 | Hoffmann La Roche | Pyrrolopyrazinkinaseinhibitors |
US8853391B2 (en) * | 2008-12-18 | 2014-10-07 | Merck Patent Gmbh | Tricyclic azaindoles |
WO2011084439A1 (en) * | 2009-12-17 | 2011-07-14 | Sanofi | Tetrahydrocarboline derivatives as eg5 inhibitors |
DK2558446T5 (da) * | 2010-04-16 | 2019-12-09 | Ac Immune Sa | Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner |
JP2018509377A (ja) * | 2014-12-05 | 2018-04-05 | サウザーン リサーチ インスチチュート | 生体アミン輸送モジュレータとしてのヘテロ環式化合物 |
EP3118202A1 (en) * | 2015-07-15 | 2017-01-18 | AC Immune S.A. | Dihydropyridopyrrole derivatives as tau-pet-ligands |
EP3322707A1 (en) * | 2015-07-15 | 2018-05-23 | AC Immune SA | Novel imaging compounds |
-
2019
- 2019-01-04 KR KR1020207018988A patent/KR102477105B1/ko active IP Right Grant
- 2019-01-04 MX MX2020007031A patent/MX2020007031A/es unknown
- 2019-01-04 SG SG11202005607WA patent/SG11202005607WA/en unknown
- 2019-01-04 CR CR20200326A patent/CR20200326A/es unknown
- 2019-01-04 EP EP19700206.6A patent/EP3735411A1/en active Pending
- 2019-01-04 MA MA051520A patent/MA51520A/fr unknown
- 2019-01-04 IL IL275781A patent/IL275781B2/en unknown
- 2019-01-04 PE PE2020000906A patent/PE20211090A1/es unknown
- 2019-01-04 CN CN201980007273.XA patent/CN111757882B/zh active Active
- 2019-01-04 CA CA3086759A patent/CA3086759A1/en active Pending
- 2019-01-04 WO PCT/EP2019/050180 patent/WO2019134978A1/en active Application Filing
- 2019-01-04 NZ NZ765495A patent/NZ765495A/en unknown
- 2019-01-04 JP JP2020537162A patent/JP7225251B2/ja active Active
- 2019-01-04 AU AU2019205087A patent/AU2019205087B2/en active Active
- 2019-01-04 BR BR112020012833-3A patent/BR112020012833A2/pt unknown
- 2019-01-04 JO JOP/2020/0167A patent/JOP20200167A1/ar unknown
-
2020
- 2020-06-29 PH PH12020500573A patent/PH12020500573A1/en unknown
- 2020-07-03 CL CL2020001796A patent/CL2020001796A1/es unknown
- 2020-07-03 CO CONC2020/0008287A patent/CO2020008287A2/es unknown
- 2020-07-22 EC ECSENADI202042640A patent/ECSP20042640A/es unknown
-
2021
- 2021-05-24 AU AU2021203340A patent/AU2021203340B2/en active Active
-
2022
- 2022-08-10 JP JP2022127608A patent/JP2022172130A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019134978A1 (en) | 2019-07-11 |
AU2019205087A1 (en) | 2020-07-02 |
AU2019205087B2 (en) | 2021-06-10 |
SG11202005607WA (en) | 2020-07-29 |
KR20200096570A (ko) | 2020-08-12 |
EP3735411A1 (en) | 2020-11-11 |
JP7225251B2 (ja) | 2023-02-20 |
NZ765495A (en) | 2024-02-23 |
MA51520A (fr) | 2021-04-14 |
BR112020012833A2 (pt) | 2021-01-05 |
AU2021203340A1 (en) | 2021-06-24 |
KR102477105B1 (ko) | 2022-12-13 |
IL275781A (en) | 2020-08-31 |
JOP20200167A1 (ar) | 2022-10-30 |
PE20211090A1 (es) | 2021-06-14 |
PH12020500573A1 (en) | 2021-05-10 |
MX2020007031A (es) | 2020-12-03 |
IL275781B1 (en) | 2023-11-01 |
CN111757882A (zh) | 2020-10-09 |
CL2020001796A1 (es) | 2021-01-22 |
IL275781B2 (en) | 2024-03-01 |
CA3086759A1 (en) | 2019-07-11 |
CO2020008287A2 (es) | 2020-10-30 |
JP2022172130A (ja) | 2022-11-15 |
CR20200326A (es) | 2020-12-09 |
JP2021510151A (ja) | 2021-04-15 |
CN111757882B (zh) | 2023-08-22 |
AU2021203340B2 (en) | 2022-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20042640A (es) | Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer | |
DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
CL2019001344A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo. | |
ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
UY31748A (es) | Nuevos compuestos para el tratamiento de trastornos del snc (sistema nervioso central) | |
NI201500031A (es) | Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos. | |
CL2011000488A1 (es) | Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus. | |
CL2012001956A1 (es) | Compuestos derivados de triazol sustituido, moduladores de la gamma secretasa; composición farmacéutica; y su uso en el tratamiento o prevención de una enfermedad como alzheimer, lesión cerebral traumática, demencia asociada con la enfermedad de parkinson, entre otras. | |
CO2019002889A2 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
CL2011002206A1 (es) | Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. | |
CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
CL2019001512A1 (es) | Tratamiento de enfermedades neurológicas. | |
CL2019001891A1 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas. | |
MX2019002429A (es) | Tratamiento de la demencia. | |
MX2017011598A (es) | Metodos para tratar proteinopatias. | |
CL2015000559A1 (es) | Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. | |
CO2019014090A2 (es) | Agentes, usos y métodos para el tratamiento | |
CO2017003321A2 (es) | Inhibidores de gingipaina de lisina | |
MX2020013115A (es) | Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau. | |
EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
ECSP20067907A (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
CR20180368A (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
MX2016008968A (es) | Compuestos organicos. | |
WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease |